Comparing Esmolol and Dexmedetomidine for Pain Control After Sinus Surgery
The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial
This study is testing whether esmolol or dexmedetomidine can help control pain better after sinus surgery for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Trial ID | NCT05703048 on ClinicalTrials.gov |
What this trial studies
This randomized trial investigates the effectiveness of esmolol versus dexmedetomidine in managing postoperative pain for patients undergoing functional endoscopic sinus surgery (FESS). The study will enroll 70 patients classified as ASA Physical Status Class I and II, who will be randomly assigned to receive either dexmedetomidine or esmolol. The randomization process will be conducted using a computer-generated list, and both patients and assessors will remain blinded to the treatment assignments. The goal is to evaluate patient satisfaction and the depth of anesthesia while minimizing opioid use.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with ASA Physical Status Class I or II scheduled for functional endoscopic sinus surgery.
Not a fit: Patients currently on beta-blockers, with certain cardiovascular conditions, or those with a history of substance abuse may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved postoperative pain management with fewer side effects and reduced reliance on opioids.
How similar studies have performed: Previous studies have shown promising results with dexmedetomidine in postoperative pain management, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 70 patients with American Society of Anesthesiologists (ASA) Physical Status Class I\&II, aged \> 18 years. and scheduled for FESS. Exclusion Criteria: * 1. The patients on β-blockers and cardiovascular active drugs 2. History of neuromuscular disorder, diabetic neuropathy, pregnancy 3. Prolonged QT interval and ventricular arrhythmia, specifically a pre-disposition to bradycardia or conduction abnormalities, cyanotic cardiac disease, and use of medications that would increase the risk of bradycardia. 4. Current (Within the last 30 days) opioid use for pain control as sickle cell disease, substance abuse or benzodiazepine addiction 5. History of end stage hepatic, renal, diabetes mellitus, and bleeding disorders, 6. Allergy and hypersensitivity to the drugs used in the study 7. Excessive use of analgesics/non-steroidal anti-inflammatory drugs 8. Morbid obesity (body mass index (BMI) \> 40) 9. A positive history of motion sickness, women who had a history of nausea and vomiting before menstruation.
Where this trial is running
Tanta
- Faculty of Medicine, Tantan University Hospital — Tanta, Egypt (Recruiting)
Study contacts
- Study coordinator: amany omara, professor
- Email: amanyfaheem2011@yahoo.com
- Phone: +201008372249
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.